Automation now the only option: Regulatory AI investment a 2025 priority due to untenable workloads, survey confirms

If the pharma/biopharma industry is to maximise affordable access for patients and maintain commercial viability as products grow ever more sophisticated, companies must become smarter in how they allocate resources to routine R&D processes, including regulatory workloads.

It is in this context that organisations are turning towards artificial intelligence (AI), and in particular next-generation technologies such as Generative AI (GenAI) powered by large language models (LLMs) – albeit that there often remain questions they need to resolve first. To understand the evolving balance between AI appetite and barriers to adoption, we recently commissioned a survey, by Censuswide, with 100 senior regulatory professionals in US pharma and biopharma organisations.

Regulatory inefficiency is spiralling